Nobivac NXT® FeLV
Next-generation vaccine providing protection against feline leukaemia virus (FeLV).
Nobivac NXT® FeLV delivers targeted protection against FeLV using innovative RNA particle technology in a single low-volume, adjuvant-free dose. 1 – 3 years of immunity gives you the choice and flexibility to tailor protocols to each cat’s lifestyle and risk level.
Cats at risk of exposure to this serious and widespread threat benefit from vaccination with Nobivac® NXT FeLV.
Key Features
- Low-volume doses (0.5 mL)
- Adjuvant-free formulations
- Innovative RNA particle technology for FeLV in cats
- Rapid 1-week onset of immunity (OOI)
- 1 – 3 years duration of immunity (DOI)
- Proven safety profile for kittens and cats*
- Approved for concurrent (non-mixed) use with Nobivac® Rabies
- Real-world results†
* First dose from 8 weeks of age.
† Nobivac NXT® FeLV has been administered in cats across North America since 2024.
Presentation
Off-white or cream-coloured lyophilisate and clear colourless solvent for suspension.
Active ingredients
Nobivac NXT® FeLV is a self-amplifying RNA particle vaccine.
Each dose (0.5 mL) of reconstituted vaccine contains feline leukaemia virus glycoprotein RNA-particle (RP): 106.6 – 109.3 RP
Indications for use
Nobivac NXT® FeLV is indicated for active immunisation of cats to reduce persistent viraemia and clinical signs caused by feline leukaemia virus (FeLV).
Onset of immunity: 1 week.
Duration of immunity: 1 year after primary vaccination, 1 – 3 years after re-vaccination.‡
‡ Until 1 year after primary vaccination or re-vaccination, a prevention in persistent viraemia and in clinical signs associated with feline leukemia virus has been demonstrated.
Contra-indications
None.
Warnings
Only vaccinate healthy animals.
Special precautions for safe use in the target species: The presence of maternally derived antibodies may interfere with the efficacy of the vaccine.
It is recommended that a test for FeLV antigenaemia be carried out prior to vaccination. Vaccination of FeLV-positive cats is of no benefit.
Do not use during pregnancy.
Side effects
Cats:
Common (1–10 animals / 100 animals treated): Injection site swelling,§ elevated temperature.||
§ 0.5–2 cm, diffuse, hard or soft, not warm and can be painful, lasting for 1 day.
|| Pyrexia (≥39.7 °C) lasting for 1 day.
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinary healthcare professional, to either the marketing authorisation holder or the national competent authority via the national reporting system. See the package leaflet for respective contact details.
Administration routes and dosage
For subcutaneous use.
Reconstitute the vial containing the lyophilisate with the supplied solvent. Ensure that the lyophilisate is completely reconstituted before use. Administer the total contents of the vial.
Reconstituted product: off-pink or pink-coloured suspension.
Vaccination schedule:
Primary vaccination: The first vaccination can be administered from 8 weeks of age, and the second vaccination 3-4 weeks later.
Re-vaccination: A single dose, administered at up to 1 year after primary vaccination, maintains protection against feline leukaemia virus. For subsequent re-vaccinations, a single dose should be administered at intervals of 1 – 3 years.
Withdrawal periods
Not applicable.
Special precautions for storage
Lyophilisate:
Store and transport refrigerated (2°–8 °C).
Do not freeze.
Protect from light.
Solvent:
No special precautions for storage.
Classification of veterinary medicinal products
Prescription decisions are for the person issuing the prescription alone.
Authorisation numbers and pack sizes
EU/2/26/370/001-002
Available in 5×1 dose and 25×1 dose packs.
Not all pack sizes may be marketed.
Legal categories
POM (ROI) POM-V (NI)
FAQs
What does Nobivac NXT® FeLV protect against?
Nobivac NXT® FeLV protects against feline leukaemia virus (FeLV).
What is the duration of immunity for Nobivac NXT® FeLV?
Nobivac NXT Felv provides immunity of 1 year after primary vaccination and 1 – 3 years after revaccination against feline leukaemia virus (Felv).
What is the onset of immunity for Nobivac NXT® FeLV?
Nobivac NXT® FeLV provides a 1-week onset of immunity following completion of the primary 2-dose vaccination series.
Can Nobivac NXT® FeLV be given at the same time with other Nobivac vaccines?
Rabies and/or the other vaccines of the Nobivac NXT range that do not contain the feline leukaemia virus glycoprotein RNA-particle component.
Can Nobivac NXT® FeLV be used in pregnancy?
Do not use during pregnancy.
What are the storage requirements for Nobivac NXT® FeLV?
Lyophilisate:
- Store and transport refrigerated (2°C–8°C)
- Do not freeze
- Protect from light
Solvent:
- No special storage precautions
Unanswered question?
Email your question and our team will reply within 2 business days.